The second-generation Bruton tyrosine kinase inhibitor tirabrutinib (ONO/GS-4059) showed promising efficacy in patients with treatment-naive (TN) or relapsed/refractory (RR) Waldenström macroglobulinemia (WM).
Inotuzumab ozogamicin (InO) exhibits clinical efficacy against heavily pretreated, relapsed CD22-positive pediatric B-cell acute lymphoblastic leukemia (B-ALL).
“Among evaluable patients who were transfusion dependent on ruxolitinib, 6 of 14 patients converted to transfusion independence after the addition of CPI-0610.”
There was no benefit observed with the use of rituximab in the maintenance setting in Waldenström macroglobulinemia.
No detectable differences were found in major response rate at 6 months and 12 months between patients with and without CXCR4 mutations.
More than half of the patients with CLL included in the retrospective study first received a novel agent in the second-line setting.
The researchers determined that in FAERS, a greater proportion of cytokine release syndrome occurred with axi-cel.
Researchers noted that bridging while awaiting CAR-T manufacturing may not be appropriate for all patients, and in some cases, bridging was associated with worse PFS and OS.
The study yielded a complete response rate of 100% across 33 subjects.
Women are less likely to be introduced by their professional title and most likely to be introduced by first name.
